Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Comparative proteomic profiling of human bile reveals SSP411 as a novel biomarker of cholangiocarcinoma.

Shen J, Wang W, Wu J, Feng B, Chen W, Wang M, Tang J, Wang F, Cheng F, Pu L, Tang Q, Wang X, Li X.

PLoS One. 2012;7(10):e47476. doi: 10.1371/journal.pone.0047476. Epub 2012 Oct 31.

2.

p38delta/MAPK13 as a diagnostic marker for cholangiocarcinoma and its involvement in cell motility and invasion.

Tan FL, Ooi A, Huang D, Wong JC, Qian CN, Chao C, Ooi L, Tan YM, Chung A, Cheow PC, Zhang Z, Petillo D, Yang XJ, Teh BT.

Int J Cancer. 2010 May 15;126(10):2353-61. doi: 10.1002/ijc.24944.

3.

Differential LC-MS-based proteomics of surgical human cholangiocarcinoma tissues.

Kawase H, Fujii K, Miyamoto M, Kubota KC, Hirano S, Kondo S, Inagaki F.

J Proteome Res. 2009 Aug;8(8):4092-103. doi: 10.1021/pr900468k.

PMID:
19569727
4.

Differences in phosphatidylcholine and bile acids in bile from Egyptian and UK patients with and without cholangiocarcinoma.

Hashim Abdalla MS, Taylor-Robinson SD, Sharif AW, Williams HR, Crossey MM, Badra GA, Thillainayagam AV, Bansi DS, Thomas HC, Waked IA, Khan SA.

HPB (Oxford). 2011 Jun;13(6):385-90. doi: 10.1111/j.1477-2574.2011.00296.x. Epub 2011 Mar 22.

5.

Genome-wide expression patterns associated with oncogenesis and sarcomatous transdifferentation of cholangiocarcinoma.

Seol MA, Chu IS, Lee MJ, Yu GR, Cui XD, Cho BH, Ahn EK, Leem SH, Kim IH, Kim DG.

BMC Cancer. 2011 Feb 19;11:78. doi: 10.1186/1471-2407-11-78.

6.

Glycoproteomics-based cancer marker discovery adopting dual enrichment with Wisteria floribunda agglutinin for high specific glyco-diagnosis of cholangiocarcinoma.

Matsuda A, Kuno A, Matsuzaki H, Kawamoto T, Shikanai T, Nakanuma Y, Yamamoto M, Ohkohchi N, Ikehara Y, Shoda J, Hirabayashi J, Narimatsu H.

J Proteomics. 2013 Jun 24;85:1-11. doi: 10.1016/j.jprot.2013.04.017. Epub 2013 Apr 21.

PMID:
23612463
7.

Proteomic profiling of cholangiocarcinoma: diagnostic potential of SELDI-TOF MS in malignant bile duct stricture.

Scarlett CJ, Saxby AJ, Nielsen A, Bell C, Samra JS, Hugh T, Baxter RC, Smith RC.

Hepatology. 2006 Sep;44(3):658-66.

PMID:
16941699
8.

An integrated approach for comparative proteomic analysis of human bile reveals overexpressed cancer-associated proteins in malignant biliary stenosis.

Lukic N, Visentin R, Delhaye M, Frossard JL, Lescuyer P, Dumonceau JM, Farina A.

Biochim Biophys Acta. 2014 May;1844(5):1026-33. doi: 10.1016/j.bbapap.2013.06.023. Epub 2013 Jul 18.

PMID:
23872482
9.

Bile carcinoembryonic cell adhesion molecule 6 (CEAM6) as a biomarker of malignant biliary stenoses.

Farina A, Dumonceau JM, Antinori P, Annessi-Ramseyer I, Frossard JL, Hochstrasser DF, Delhaye M, Lescuyer P.

Biochim Biophys Acta. 2014 May;1844(5):1018-25. doi: 10.1016/j.bbapap.2013.06.010. Epub 2013 Jun 24.

PMID:
23806607
10.

A prospective proteomic-based study for identifying potential biomarkers for the diagnosis of cholangiocarcinoma.

Shi Y, Deng X, Zhan Q, Shen B, Jin X, Zhu Z, Chen H, Li H, Peng C.

J Gastrointest Surg. 2013 Sep;17(9):1584-91. doi: 10.1007/s11605-013-2182-9. Epub 2013 Jul 19.

11.

Identification of novel biomarker candidates for the immunohistochemical diagnosis of cholangiocellular carcinoma.

Padden J, Megger DA, Bracht T, Reis H, Ahrens M, Kohl M, Eisenacher M, Schlaak JF, Canbay AE, Weber F, Hoffmann AC, Kuhlmann K, Meyer HE, Baba HA, Sitek B.

Mol Cell Proteomics. 2014 Oct;13(10):2661-72. doi: 10.1074/mcp.M113.034942. Epub 2014 Jul 17.

12.

Gene expression profiling of cholangiocarcinoma-derived fibroblast reveals alterations related to tumor progression and indicates periostin as a poor prognostic marker.

Utispan K, Thuwajit P, Abiko Y, Charngkaew K, Paupairoj A, Chau-in S, Thuwajit C.

Mol Cancer. 2010 Jan 24;9:13. doi: 10.1186/1476-4598-9-13.

13.

The Prognostic Role of SOCS3 and A20 in Human Cholangiocarcinoma.

Wang Y, Wan M, Zhou Q, Wang H, Wang Z, Zhong X, Zhang L, Tai S, Cui Y.

PLoS One. 2015 Oct 20;10(10):e0141165. doi: 10.1371/journal.pone.0141165. eCollection 2015.

14.

Metabolic profiling of bile in cholangiocarcinoma using in vitro magnetic resonance spectroscopy.

Sharif AW, Williams HR, Lampejo T, Khan SA, Bansi DS, Westaby D, Thillainayagam AV, Thomas HC, Cox IJ, Taylor-Robinson SD.

HPB (Oxford). 2010 Aug;12(6):396-402. doi: 10.1111/j.1477-2574.2010.00185.x.

15.

Array comparative genomic hybridization identifies novel potential therapeutic targets in cholangiocarcinoma.

McKay SC, Unger K, Pericleous S, Stamp G, Thomas G, Hutchins RR, Spalding DR.

HPB (Oxford). 2011 May;13(5):309-19. doi: 10.1111/j.1477-2574.2010.00286.x. Epub 2011 Mar 10.

16.

Tumoral heterogeneity of hepatic cholangiocarcinomas revealed by MALDI imaging mass spectrometry.

Le Faouder J, Laouirem S, Alexandrov T, Ben-Harzallah S, L├ęger T, Albuquerque M, Bedossa P, Paradis V.

Proteomics. 2014 Apr;14(7-8):965-72. doi: 10.1002/pmic.201300463.

PMID:
24678008
17.

Serum levels of variants of transthyretin down-regulation in cholangiocarcinoma.

Liu L, Wang J, Liu B, Dai S, Wang X, Chen J, Huang L, Xiao X, He D.

J Cell Biochem. 2008 Jun 1;104(3):745-55. doi: 10.1002/jcb.21661.

PMID:
18275060
18.

Annexin A1: A new immunohistological marker of cholangiocarcinoma.

Hongsrichan N, Rucksaken R, Chamgramol Y, Pinlaor P, Techasen A, Yongvanit P, Khuntikeo N, Pairojkul C, Pinlaor S.

World J Gastroenterol. 2013 Apr 28;19(16):2456-65. doi: 10.3748/wjg.v19.i16.2456.

20.

Cholangiocarcinoma Heterogeneity Revealed by Multigene Mutational Profiling: Clinical and Prognostic Relevance in Surgically Resected Patients.

Ruzzenente A, Fassan M, Conci S, Simbolo M, Lawlor RT, Pedrazzani C, Capelli P, D'Onofrio M, Iacono C, Scarpa A, Guglielmi A.

Ann Surg Oncol. 2016 May;23(5):1699-707. doi: 10.1245/s10434-015-5046-6. Epub 2015 Dec 30.

PMID:
26717940

Supplemental Content

Support Center